Influence of adverse drug reactions on treatment success: Prospective cohort analysis of HIV-infected individuals initiating first-line antiretroviral therapy in India

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Shet, Anita ^a,c   Antony, Jimmy ^a   Arumugam, Karthika ^a   Kumar Dodderi, Sunil ^b   Rodrigues, Rashmi ^a   DeCosta, Ayesha ^c  

^a ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

^b GOVERNMENT OF INDIA   (India)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; COTRIMOXAZOLE; EFAVIRENZ; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS STAVUDINE; ZIDOVUDINE;

ABDOMINAL PAIN; ADULT; ANEMIA; ARTICLE; ATTITUDE TO HEALTH; BLOOD TRANSFUSION; BODY MASS; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DYSLIPIDEMIA; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERLACTATEMIA; HYPERPIGMENTATION; HYPERTRANSAMINASEMIA; INCIDENCE; INDIA; INSOMNIA; LACTIC ACIDOSIS; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MYALGIA; NAIL DISEASE; NAIL HYPERPIGMENTATION; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PANCREATITIS; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT COUNSELING; PERIPHERAL NEUROPATHY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; RISK ASSESSMENT; RISK REDUCTION; SEX DIFFERENCE; THROMBOCYTOPENIA; VIRUS LOAD; VOMITING; ADOLESCENT; ADVERSE EFFECTS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; MIDDLE AGED; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; INDIA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84897522443     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091028     Document Type: Article

References (43)

1. Murphy RA, Sunpath H, Kuritzkes DR, Venter F, Gandhi RT (2007) Antiretroviral therapy-associated toxicities in the resource-poor world: the challenge of a limited formulary. J Infect Dis 196 Suppl 3: S449-456. (Pubitemid 351417238)
2. Max B, Sherer R (2000) Management of the adverse effects of antiretroviral therapy and medication adherence. Clinical Infectious Diseases 30 Suppl 2: S96-116.
3. O'Brien ME, Clark RA, Besch CL, Myers L, Kissinger P (2003) Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr 34: 407-414. (Pubitemid 37444469)
4. Cicconi P, Cozzi-Lepri A, Castagna A, Trecarichi EM, Antinori A, et al. (2010) Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naive patients. HIV Med 11: 104-113.
5. National AIDS Control Organisation Annual Report, 2012-2013. Department of AIDS Control. Ministry of Health and Family Welfare, New Delhi. Available: http://www.naco.gov.in/NACO/Quick-Links/Publication/Annual-Report/ NACO-Annual-Report/Annual-Report-2012-13. Accessed 20 Jan 2014.
6. World Health Organization (2013) WHO issues new HIV recommendations calling for earlier treatment. Available: http://www.who.int/mediacentre/news/ releases/2013/new-hiv-recommendations-20130630/en/index.html. Accessed 15 Dec 2014.
7. De Costa A, Shet A, Kumarasamy N, Ashorn P, Eriksson B, et al. (2010) Design of a randomized trial to evaluate the influence of mobile phone reminders on adherence to first line antiretroviral treatment in South India - the HIVIND study protocol. BMC Med Res Methodol 10: 25.
8. National AIDS Control Organization (2007) Antiretroviral therapy guidelines for HIV-infected adults and adolescents including post-exposure prophylaxis, New Delhi: Ministry of Health & Family Welfare, Government of India. Available: http://www.naco.gov.in/NACO/About-NACO/Policy-Guidelines/ Policies-Guidelines1/. Accessed 20 Dec 2013.
9. World Health Organization International drug monitoring: the role of national centers. Geneva; 1972. WHO Technical Report Series 498.
10. National Institutes of Health Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, December 2004, Clarification Aug 2009. Available: http://rsc.tech-res.com/document/safetyandpharma covigilance/table-for-grading-severity-of-adult-pediatric-adverse-events.pdf. Accessed 20 December 2013.
11. Edwards IR, Aronson JK (2000) Adverse drug reactions: definitions, diagnosis, and management. Lancet 356: 1255-1259.
12. World Health Organization (2001) Iron deficiency anaemia: assessment, prevention and control. A guide for programme managers. Geneva.
13. Campbell TB, Smeaton LM, Kumarasamy N, Flanigan T, Klingman KL, et al. (2012) Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings. PLoS Med 9: e1001290.
14. Khalili H, Dashti-Khavidaki S, Mohraz M, Etghani A, Almasi F (2009) Antiretroviral induced adverse drug reactions in Iranian human immunodeficiency virus positive patients. Pharmacoepidemiol Drug Saf 18: 848-857.
15. Agu KA, Oparah AC (2013) Adverse drug reactions to antiretroviral therapy: Results from spontaneous reporting system in Nigeria. Perspect Clin Res 4: 117-124.
16. Perovic Mihanovic M, Haque NS, Rutherford GW, Zekan S, Begovac J (2013) Toxicity-related antiretroviral drug treatment modifications in individuals starting therapy: a cohort analysis of time patterns, sex, and other risk factors. Med Sci Monit 19: 483-492.
17. Namme Luma H, Doualla MS, Choukem SP, Temfack E, Ashuntantang G, et al. (2012) Adverse drug reactions of Highly Active Antiretroviral Therapy (HAART) in HIV infected patients at the General Hospital, Douala, Cameroon: a cross sectional study. Pan Afr Med J 12: 87.
18. Prosperi MC, Fabbiani M, Fanti I, Zaccarelli M, Colafigli M, et al. (2012) Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study. BMC Infect Dis 12: 296.
19. Eluwa GI, Badru T, Agu KA, Akpoigbe KJ, Chabikuli O, et al. (2012) Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria. BMC Clin Pharmacol 12: 7.
20. Keiser O, Fellay J, Opravil M, Hirsch HH, Hirschel B, et al. (2007) Adverse events to antiretrovirals in the Swiss HIV Cohort Study: effect on mortality and treatment modification. Antivir Ther 12: 1157-1164.
21. Severe P, Leger P, Charles M, Noel F, Bonhomme G, et al. (2005) Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med 353: 2325-2334. (Pubitemid 41713744)
22. Kumarasamy N, Venkatesh KK, Cecelia AJ, Devaleenal B, Lai AR, et al. (2008) Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients. AIDS Patient Care STDS 22: 337-344. (Pubitemid 351562965)
23. Modayil RR, Harugeri A, Parthasarathi G, Ramesh M, Prasad R, et al. (2010) Adverse drug reactions to antiretroviral therapy (ART): an experience of spontaneous reporting and intensive monitoring from ART centre in India. Pharmacoepidemiol Drug Saf 19: 247-255.
24. Srikanth BA, Babu SC, Yadav HN, Jain SK (2012) Incidence of adverse drug reactions in human immune deficiency virus-positive patients using highly active antiretroviral therapy. J Adv Pharm Technol Res 3: 62-67.
25. Sivadasan A, Abraham OC, Rupali P, Pulimood SA, Rajan J, et al. (2009) High rates of regimen change due to drug toxicity among a cohort of South Indian adults with HIV infection initiated on generic, first-line antiretroviral treatment. J Assoc Physicians India 57: 384-388.
26. Robison LS, Westfall AO, Mugavero MJ, Kempf MC, Cole SR, et al. (2008) Short-term discontinuation of HAART regimens more common in vulnerable patient populations. AIDS Res Hum Retroviruses 24: 1347-1355.
27. Bersoff-Matcha SJ, Miller WC, Aberg JA, van Der Horst C, Hamrick Jr HJ, et al. (2001) Sex differences in nevirapine rash. Clin Infect Dis 32: 124-129. (Pubitemid 32150957)
28. Antinori A, Baldini F, Girardi E, Cingolani A, Zaccarelli M, et al. (2001) Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy. AIDS 15: 1579-1581. (Pubitemid 32744607)
29. Kesselring AM, Wit FW, Sabin CA, Lundgren JD, Gill MJ, et al. (2009) Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. AIDS 23: 1689-1699.
30. Ofotokun I, Chuck SK, Hitti JE (2007) Antiretroviral pharmacokinetic profile: a review of sex differences. Gend Med 4: 106-119. (Pubitemid 47248489)
31. Lichtenstein KA, Armon C, Buchacz K, Chmiel JS, Moorman AC, et al. (2008) Initiation of antiretroviral therapy at CD4 cell counts >/ = 350 cells/mm3 does not increase incidence or risk of peripheral neuropathy, anemia, or renal insufficiency. J Acquir Immune Defic Syndr 47: 27-35. (Pubitemid 351619366)
32. Moh R, Danel C, Sorho S, Sauvageot D, Anzian A, et al. (2005) Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Cote d'Ivoire. Antivir Ther 10: 615-624. (Pubitemid 41224953)
33. Ssali F, Stohr W, Munderi P, Reid A, Walker AS, et al. (2006) Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial. Antivir Ther 11: 741-749. (Pubitemid 44497169)
34. Phe T, Thai S, Veng C, Sok S, Lynen L, et al. (2013) Risk factors of treatment-limiting anemia after substitution of zidovudine for stavudine in HIV-infected adult patients on antiretroviral treatment. PLoS One 8: e60206.
35. Zhou J, Jaquet A, Bissagnene E, Musick B, Wools-Kaloustian K, et al. (2012) Short-term risk of anaemia following initiation of combination antiretroviral treatment in HIV-infected patients in countries in sub-Saharan Africa, Asia-Pacific, and central and South America. J Int AIDS Soc 15: 5.
36. Rajesh R, Vidyasagar S, Varma DM, Mohiuddin S, Noorunnisa (2011) Evaluation of incidence of zidovudine induced anemia in Indian human immunodeficiency virus positive patients in comparison with stavudine based highly active antiretroviral therapy. Int J Risk Saf Med 23: 171-180.
37. World Health Organization (2013) Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. June 2013. Geneva: WHO. Available: http://www.who.int/hiv/pub/guidelines/arv2013/download/en/index.html. Accessed 20 December 2013.
38. Anuradha S, Joshi A, Negi M, Nischal N, Rajeshwari K, et al. (2013) Factors influencing adherence to ART: new insights from a center providing free ART under the national program in Delhi, India. J Int Assoc Provid AIDS Care 12: 195-201.
39. d'Arminio Monforte A, Lepri AC, Rezza G, Pezzotti P, Antinori A, et al. (2000) Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS 14: 499-507. (Pubitemid 30209692)
40. Ruud KW, Srinivas SC, Toverud EL (2012) Healthcare providers' experiences with adverse drug reactions and adherence challenges in antiretroviral therapy of HIV patients in the Eastern Cape Province, South Africa. Eur J Clin Pharmacol 68: 1321-1328.
41. Elzi L, Marzolini C, Furrer H, Ledergerber B, Cavassini M, et al. (2010) Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med 170: 57-65.
42. Lodwick RK, Smith CJ, Youle M, Lampe FC, Tyrer M, et al. (2008) Stability of antiretroviral regimens in patients with viral suppression. AIDS 22: 1039-1046. (Pubitemid 351769742)
43. Yuan Y, L'Italien G, Mukherjee J, Iloeje UH (2006) Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort. HIV Med 7: 156-162. (Pubitemid 43337594)